Locations:
SearchAdvertisement
Treatment assigned FDA review date in June 2025
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization
Long-acting antiemetics and high-dose steroids key to minimizing acute nausea
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Greater awareness among young patients is needed
Neoadjuvant immunotherapy improves outcomes
Use of GLP-1s and improving cardiovascular health lowers risk of hematologic malignancies
Poor response may be due to different tumor biology
Study sheds light on distant metastasis rates between upfront surgery and Watch & Wait strategies
Findings confirm microbial variability, offer new potential treatment strategy
Advertisement
Advertisement